NYSEAMERICAN:CVRSCorindus Vascular Robotics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Corindus Vascular Robotics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.27 0.00 (0.00 %) (As of 11/27/2019) Add Compare Share Today's Range$4.27Now: $4.27▼$4.2750-Day Range N/A52-Week Range$0.78Now: $4.27▼$4.40VolumeN/AAverage Volume1.99 million shsMarket Capitalization$891.08 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingCorindus Vascular Robotics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.28, Corindus Vascular Robotics has a potential upside of 0.2% from its current price of $4.27.Amount of Analyst CoverageCorindus Vascular Robotics has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCorindus Vascular Robotics has received 407 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCorindus Vascular Robotics has received 465 “underperform” votes. (Add your “underperform” vote.)Community SentimentCorindus Vascular Robotics has received 53.33% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote “Outperform” if you believe CVRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CVRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCorindus Vascular Robotics does not currently pay a dividend.Dividend GrowthCorindus Vascular Robotics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corindus Vascular Robotics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.66 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Medical Appliances & Equipment Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:CVRS Previous SymbolNYSEMKT:CVRS CUSIPN/A CIKN/A Webwww.corindus.com Phone+1-508-6533335Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees90 Outstanding Shares208,685,000Market Cap$891.08 million Next Earnings DateN/A OptionableNot Optionable $4.27 0.00 (0.00 %) (As of 11/27/2019) 30 days | 90 days | 365 days | Advanced Chart Receive CVRS News and Ratings via Email Sign-up to receive the latest news and ratings for CVRS and its competitors with MarketBeat's FREE daily newsletter. Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Corindus Vascular Robotics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corindus Vascular Robotics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Corindus Vascular Robotics. How were Corindus Vascular Robotics' earnings last quarter? Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) released its quarterly earnings data on Tuesday, August, 7th. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.01. The medical equipment provider earned $1.67 million during the quarter, compared to analysts' expectations of $3 million. View Corindus Vascular Robotics' earnings history. What price target have analysts set for CVRS? 1 brokerages have issued 12 month target prices for Corindus Vascular Robotics' shares. Their forecasts range from $4.28 to $4.28. On average, they anticipate Corindus Vascular Robotics' stock price to reach $4.28 in the next twelve months. This suggests a possible upside of 0.2% from the stock's current price. View analysts' price targets for Corindus Vascular Robotics. Has Corindus Vascular Robotics been receiving favorable news coverage? Headlines about CVRS stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Corindus Vascular Robotics earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Corindus Vascular Robotics. Who are some of Corindus Vascular Robotics' key competitors? Some companies that are related to Corindus Vascular Robotics include Consort Medical (CSRT), Ekf Diagnostics (EKF), Immunodiagnostic Systems (IDH), Theralase Technologies (TLT), Intelligent Ultrasound Group (MED), LiDCO Group (LID), InspireMD (NSPR), Deltex Medical Group (DEMG), Zecotek Photonics (ZMS), Lucid (LCDX), MCP Income Opp Trust Ordinary Units FP (MOT) and Verisante Technology (VRS). View all competitors. What other stocks do shareholders of Corindus Vascular Robotics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXC), Micron Technology (MU), Advanced Micro Devices (AMD), Helios and Matheson Analytics (HMNY), Alibaba Group (BABA), TherapeuticsMD (TXMD), Exelixis (EXEL), NVIDIA (NVDA) and Protalix Biotherapeutics (PLX). Who are Corindus Vascular Robotics' key executives? Corindus Vascular Robotics' management team includes the following people: Mr. Mark J. Toland, CEO, Pres & Director (Age 49)Mr. David W. Long, CFO, Sr. VP, Sec. & Treasurer (Age 49)Mr. Douglas Teany, Chief Operating Officer (Age 47)Ms. Nora Dutta, Sr. VP of HRDr. J. Aaron Grantham, Chief Medical Officer of Cardiovascular What is Corindus Vascular Robotics' stock symbol? Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS." How do I buy shares of Corindus Vascular Robotics? Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Corindus Vascular Robotics' stock price today? One share of CVRS stock can currently be purchased for approximately $4.27. How big of a company is Corindus Vascular Robotics? Corindus Vascular Robotics has a market capitalization of $891.08 million. Corindus Vascular Robotics employs 90 workers across the globe. What is Corindus Vascular Robotics' official website? The official website for Corindus Vascular Robotics is www.corindus.com. How can I contact Corindus Vascular Robotics? Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335. This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
